Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M312078200 on March 15, 2004

J. Biol. Chem., Vol. 279, Issue 21, 21759-21765, May 21, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/21/21759    most recent
M312078200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ju, S.
Right arrow Articles by Greenberg, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ju, S.
Right arrow Articles by Greenberg, M. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Human 1-D-myo-Inositol-3-phosphate Synthase Is Functional in Yeast*

Shulin Ju{ddagger}, Galit Shaltiel§, Alon Shamir§, Galila Agam§, and Miriam L. Greenberg{ddagger}

From the {ddagger}Department of Biological Sciences, Wayne State University, Detroit, Michigan 48202 and the §Stanley Research Center, Zlotowski Center for Neuroscience and Department of Clinical Biochemistry, Ben-Gurion University of the Negev, and Beersheva Mental Health Center, Beersheva, Israel 84170

Received for publication, November 4, 2003 , and in revised form, March 4, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
We have cloned, sequenced, and expressed a human cDNA encoding 1-D-myo-inositol-3-phosphate (MIP) synthase (hINO1). The encoded 62-kDa human enzyme converted D-glucose 6-phosphate to 1-D-myo-inositol 3-phosphate, the rate-limiting step for de novo inositol biosynthesis. Activity of the recombinant human MIP synthase purified from Escherichia coli was optimal at pH 8.0 at 37 °C and exhibited Km values of 0.57 mM and 8 µM for glucose 6-phosphate and NAD+, respectively. and K+ were better activators than other cations tested (Na+, Li+, Mg2+, Mn2+), and Zn2+ strongly inhibited activity. Expression of the protein in the yeast ino1{Delta} mutant lacking MIP synthase (ino1{Delta}/hINO1) complemented the inositol auxotrophy of the mutant and led to inositol excretion. MIP synthase activity and intracellular inositol were decreased about 35 and 25%, respectively, when ino1{Delta}/hINO1 was grown in the presence of a therapeutically relevant concentration of the anti-bipolar drug valproate (0.6 mM). However, in vitro activity of purified MIP synthase was not inhibited by valproate at this concentration, suggesting that inhibition by the drug is indirect. Because inositol metabolism may play a key role in the etiology and treatment of bipolar illness, functional conservation of the key enzyme in inositol biosynthesis underscores the power of the yeast model in studies of this disorder.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Inositol, a six-carbon cyclitol, is found ubiquitously in biological systems (1–3). myo-Inositol, physiologically the most important stereoisomer of inositol, is the precursor of all inositol-containing compounds including phosphoinositides, inositol phosphates, and cell wall polysaccharides (4). These inositol-containing metabolic products convey signals for a wide variety of hormones, growth factors, and neurotransmitters (5–7), and their metabolism plays a vital role in growth regulation, signal transduction, transcription regulation, membrane biogenesis, and other essential biochemical processes (4, 8, 9).

Inositol metabolism is implicated in the etiology and treatment of bipolar disorder, a severe psychiatric illness that affects 1–2% of the general population (10). Lithium and valproate (VPA)1 are the two FDA-approved drugs for the treatment of bipolar disorder. The cause of this illness is unknown, and the therapeutic mechanisms of the anti-bipolar drugs have not been elucidated. The possibility that inositol metabolism is involved in the etiology of bipolar disorder is supported by findings of aberrant inositol metabolism in bipolar patients (11). Reduced frontal cortex inositol levels and reduced levels of phosphatidylinositol bisphosphate in platelet membrane from bipolar patients have been reported (12–14). In addition, inositol incorporation into membrane phosphoinositides of lymphoblastoid cell lines derived from bipolar patients is reduced (15).

The inositol depletion hypothesis has been proposed to explain the therapeutic mechanism of Li (16, 17) based on the observed uncompetitive inhibition of inositol monophosphatase by Li (16, 18) resulting in decreased inositol and down-regulation of the phosphoinositide cycle. An argument raised against the inositol depletion hypothesis is that VPA does not affect inositol monophosphatase (19), which is, thus, not a common target of the drugs. However, we have shown that VPA decreases intracellular inositol in yeast (20), although it does not inhibit inositol monophosphatase (21). Similar to what is found in yeast, a reduced level of inositol also was reported in rodent brain after acute2 and chronic (23) administration of VPA.

Although a number of metabolic routes emanate from myo-inositol, de novo synthesis of inositol is carried out by one set of enzymatic reactions in all organisms studied to date. D-Glucose 6-phosphate (G-6-P) is converted to 1-D-myo-inositol-3-phosphate (MIP), which is subsequently dephosphorylated to myo-inositol. The rate-limiting step in inositol de novo biosynthesis is the conversion of G-6-P to MIP, a three-step reaction catalyzed by the enzyme 1-D-myo-inositol-3-phosphate synthase (EC 5.5.1.4 [EC] ), including an oxidation step with NAD+ serving as a hydrogen acceptor, an intramolecular aldol cyclization step, and finally a reduction step with NADH acting as the hydrogen donor regenerating NAD+ (1). MIP synthase has been purified or partially purified and characterized from a wide range of organisms, and its active form is a multimer of identical subunits ranging in molecular mass from 58 to 67 kDa (1–3, 24–28). The structural gene (INO1) encoding the MIP synthase subunit was first identified and cloned in Saccharomyces cerevisiae (27). Homologs of this gene subsequently have been cloned from several prokaryotic and eukaryotic microorganisms and higher plants (1, 3, 29, 30).

The best studied MIP synthase is the enzyme from S. cerevisiae in which expression has been characterized at the molecular level. INO1 expression is regulated by precursors of phospholipid biosynthesis, inositol and choline (31–36). INO1 is fully repressed in the presence of inositol and choline and derepressed more than 10-fold in their absence. Derepression of INO1 when inositol is limiting is brought about by the positive transcriptional activators Ino2p and Ino4p. In the presence of inositol, the negative regulator Opi1p represses transcription of INO1 (37). Because inositol metabolism is so well characterized in yeast, we have utilized this model system to elucidate the effects of anti-bipolar drugs on this pathway. Employing genetic and molecular approaches to identify common targets of Li and VPA in S. cerevisiae, we have shown that both Li and VPA affect the inositol metabolic pathway. Both drugs cause a decrease in intracellular myo-inositol and an increase in expression of INO1 as well as the regulatory gene INO2 required for inositol biosynthesis (20). In addition, both drugs lead to a decrease in the phosphatidylinositol/phosphatidylcholine ratio (38). Furthermore, VPA abrogates the normal response to inositol depletion of inositol-responsive genes and leads to aberrant synthesis of phospholipids (39).

Given the essential role of inositol in cellular function, surprisingly little is known about the regulation of MIP synthase in human cells. Despite some studies on the biochemistry of the enzyme from various animal systems (40–43), the INO1 gene has not been cloned from these sources. Recently, Guan et al. (29) reported the molecular cloning of the putative human MIP synthase cDNA. However, functional expression of the cDNA and characterization of the enzyme was not carried out.

In this study, we cloned the human MIP synthase cDNA and characterized the recombinant enzyme. We show for the first time that the human enzyme is functional in yeast. Furthermore, human MIP synthase activity was decreased in cells grown in the presence of VPA. Because inositol metabolism is thought to play a key role in the etiology and treatment of bipolar illness, conservation of function of this key enzyme underscores the power of the yeast model in studies of this illness.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—All chemicals used were reagent grade or better. Glucose, yeast extract, and peptone were purchased from Difco. Amino acids, NAD+, myo-inositol, glucose 6-phosphate, imidazole, lysozyme, valproate, ampicillin, and chloramphenicol were obtained from Sigma. [14C]Glucose 6-phosphate, [14C]inositol, and [32P]UTP were bought from PerkinElmer Life Sciences. Protease inhibitor tablets were from Roche Applied Science. pRSETA vector, anti-Xpress antibody, and Ni2+-chelated resin were purchased from Invitrogen. Dialysis tubing was made by Spectrum Laboratories Inc.

Strains, Media, and Growth Conditions—The S. cerevisiae strains used in this study are ino1{Delta} (derivative of BY4741, his3–1 leu2–0 met15–0 ura3–0 ino1::KanMX MAT a) and wild type BY4741 (isogenic except for INO1), and the indicator strain AID-1 (a/{alpha}, ade1/ade1, ino1–13/ino1–13, lys2/+). Yeast strains were grown at 30 °C. Synthetic medium contained glucose (2% w/v), necessary supplements adenine (20 mg liter–1), arginine (20 mg liter–1), lysine (20 mg liter–1), methionine (20 mg liter–1), threonine (300 mg liter–1), histidine (10 mg liter–1), leucine (60 mg liter–1), tryptophan (20 mg liter–1), and uracil (40 mg liter–1), and the salts and vitamin components of Difco vitamin-free yeast base, plus agar (2% w/v) for plates. Complex medium (YPD plates) contained glucose (2% w/v), bactopeptone (2% w/v), yeast extract (1% w/v), and agar (2% w/v). The Escherichia coli strain used is BL21(DE3)pLysS (F– ompT hsdSB(r –Bm –B)gal dcm (DE3) pLysS (Cam R)). E. coli cells were grown at 37 °C. LB medium contained tryptone (1% w/v), yeast extract (0.5% w/v), and NaCl (1% w/v). Plates contained 1.5% agar.

Isolation of Human MIP Synthase cDNA—A post-mortem human prefrontal cortex specimen derived from a brain collection described previously (44) was used for mRNA purification. mRNA was purified using the Quick-Prep micro mRNA purification kit (Amersham Biosciences) according to the manual. Amplification of the human MIP synthase cDNA was performed as follows. First strand cDNA synthesis was carried out using the first strand cDNA synthesis kit (Amersham Biosciences) with the reverse primer 5'-GGGGGCCTTCAAGGTAGG-3'. The cDNA was amplified using the forward (5'-GCCGCCGCTGCCTGAGTCGAC-3') and reverse (5'-GGGGGCCTTCAAGGTAGG-3') specific primers. Amplification of the open reading frame was performed using the PCR product from the first reaction as a template along with a forward primer supplemented with a BamHI restriction site (5'-GCGCCGGGATCCACGATGGAGGCCGCCGCCCAG-3') and a reverse primer supplemented with an XhoI site (5'-CTAGACTCGAGGGTGGTGGGCATTGGG-3'). The PCR product was cut by BamHI and XhoI and inserted into pRS426GPD and pRSETA vectors. All constructs were confirmed by sequencing.

Measurement of Intracellular Inositol—Intracellular inositol was measured as described (39). Briefly, cells were washed three times and resuspended in water (~1 ml/g cells), and glass beads were added to ~50% of the volume of the suspension. Each sample was vortexed for 10 min at 2-min intervals alternating with 2-min incubations on ice. The cell extracts were clarified by centrifugation for 2 min at 2,000 x g, and the supernatants were transferred to Eppendorf tubes and centrifuged for 15 min at 14,000 x g. The supernatants were collected and frozen at –80 °C. Intracellular inositol mass per 100 µg of protein was determined by the enzyme-coupled fluorescence assay (45).

Measurement of hINO1 Expression—Ino1{Delta}/hINO1 cells (the ino1{Delta} mutant transformed with the hINO1 gene on pRS426GPD) were grown in Ura– synthetic medium in the presence or absence of 0.6 mM VPA to the early stationary phase of growth. Northern analysis was performed as described (39). RNA probes for Northern analysis were synthesized from plasmids linearized with restriction enzymes as follows. The plasmid, restriction enzyme, and RNA polymerase for hINO1 are pGEM-hINO1, StuI, and SP6, respectively, and for TCM1 are pAB309, EcoRI, and SP6, respectively.

Overexpression of Human MIP Synthase in E. coli—The recombinant constructs were transformed into E. coli BL21(DE3)pLysS for expression of the protein. A single colony of BL21(DE3)pLysS containing the recombinant pRSETA/hINO1 was inoculated into 5 ml of LB medium containing 100 µg/ml ampicillin and 35 µg/ml chloramphenicol. The culture was incubated overnight and used to inoculate 200 ml of LB medium with the same concentration of ampicillin and chloramphenicol. Cell pellets from 200-ml cultures were used to inoculate 8 liters of fresh LB medium containing 25 µg/ml ampicillin and 35 µg/ml chloramphenicol. These cultures were grown at 37 °C to an A550 of 0.4. Production of recombinant protein was induced by the addition of isopropyl-1-thio-{beta}-D-galactopyranoside to a final concentration of 1 mM followed by incubation for 3 h. Cells were harvested by centrifugation and stored at –80 °C until needed.

Purification of Recombinant Human MIP Synthase—All the purification steps were carried out at 4 °C. Frozen cells (10 g from 8 liters of culture) were thawed and resuspended in 150 ml of binding buffer (50 mM NaPO4, 0.5 M NaCl, 10 mM imidazole, 0.1x protease inhibitor, pH 8.0). The cell suspension was incubated with 100 mg of lysozyme on ice for 30 min and then lysed by sonication 10 times for 30 s on ice. DNase (5 µg/ml) and RNase (10 µg/ml) were added, and this was followed by incubation on ice for another 15 min. The supernatant was separated from cell debris by centrifugation (10,000 rpm for 15 min, SS34 rotor), loaded onto a Ni2+ column (Invitrogen), and allowed to bind with resin for 60 min using gentle agitation to keep the resin suspended. The purification column was then washed five times with 200 ml of washing buffer (50 mM NaPO4, 0.5 M NaCl, 20 mM imidazole, pH 7.0) and eluted with 60 ml of eluting buffer (50 mM NaPO4, 0.5 M NaCl, 250 mM imidazole, pH 8.0). One-ml fractions were collected and analyzed by SDS-PAGE. The peak fractions containing MIP synthase were combined and loaded onto another Ni2+ column. The column was washed and the enzyme was eluted with imidazole.

Dialysis—Spectrum Spectra/Por molecularporous membrane dialysis tubing (MWCO 50 kDa, Rancho Dominguez, CA) was prepared according to the suggested protocol. 10-cm strips were cut and soaked in sterile distilled H2O for 10 min. The tubing was filled to 60% of capacity, leaving a small air pocket at one end of the tube. Both ends of the tube were clamped, and the tube was soaked in 4 liters of precooled buffer (1 mM Tris acetate, pH 8.0, 0.05 mM dithiothreitol, 0.025x protease inhibitor). Dialysis was carried out for 36 h at 4 °C with the buffer changed every 12 h.

Protein Assay—Protein concentration was determined by the method of Bradford (46) using bovine serum albumin as the standard.

Electrophoresis and Western Blot—SDS-PAGE was performed on Ready Gel (4–20% gradient) from Bio-Rad. Electrophoresis was carried out using the procedure described by Laemmli (47). All gels were stained with Coomassie Brilliant Blue R-250 (Bio-Rad). Western blots were performed by standard procedures using a mouse-derived monoclonal antibody against Xpress (Invitrogen) for protein expressed in E. coli, and alkaline phosphatase goat anti-mouse IgG (Promega) as a secondary antibody.

MIP Synthase Assay—MIP synthase was assayed in crude extracts by the chromatographic method of Chen and Charalampous (48). Purified MIP synthase activity was determined by the rapid colorimetric method of Barnett et al. (49) with minor modification. Purified protein was incubated in the reaction buffer in a final volume of 150 µl (100 mM Tris acetate, pH 8.0, 5 mM G-6-P, 0.8 mM NAD+, 2 mM dithiothreitol, if not otherwise indicated) for 1 h at 37 °C. 14 mM NH+4 was included in the assays for determining optimal pH, temperature, and Km. The reaction was terminated by the addition of 50 µl of 20% (w/v) trichloroacetic acid and kept on ice for 10 min. The precipitated protein was removed by centrifugation. 200 µl of the supernatant was incubated with 200 µl of NaIO4 for 1 h. 200 µl of 1 M Na2SO3 then was added to the supernatant to remove the excess NaIO4. For the measurement of phosphate, a 600-µl reagent mixture (240 µl of H2O, 120 µl of 2.5% ammonium molybdate, 120 µl of 10% ascorbic acid, and 120 µl of 6 N sulfuric acid) was added and incubated for 1 h at 37 °C. The absorbance was measured at 820 nm, and specific activity was defined as units per mg of protein where 1 unit is the amount of enzyme catalyzing the formation of 1 nmol of product per min at 37 °C. For each assay, a second aliquot of the sample was measured for phosphates not released by periodate to control for phosphatase activity. This value was subtracted from the experimental sample to obtain synthase activity.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Isolation of the Human MIP Synthase cDNA
A full-length human MIP synthase cDNA (1677 bp) was isolated from post-mortem brain as described under "Experimental Procedures." The cDNA encodes a protein of 558 amino acids with a molecular mass of ~62 kDa. The deduced protein is 50% identical and 69% similar to MIP synthase from S. cerevisiae (Fig. 1).



View larger version (55K):
[in this window]
[in a new window]
  		FIG. 1.
Alignment of the human and yeast MIP synthase amino acid sequences. The comparison was carried out using the ClustalW program. Asterisk indicates identical regions; period and colon indicate conserved regions.

 
Functional Expression of Human MIP Synthase cDNA
A yeast-based functional assay was employed to determine whether the cDNA encoded a functional MIP synthase. To perform the assay, hINO1 was cloned into the yeast expression vector pRS426GPD, which is constitutively expressed in high copy (50). This vector was transformed into the yeast ino1{Delta} mutant, which cannot synthesize inositol because of the disrupted INO1 gene. As shown in Fig. 2A, the ino1{Delta} mutant transformed with hINO1 (ino1{Delta}/hINO1) grew on a plate lacking inositol (I–), in contrast to mutant cells transformed with empty vector (ino1{Delta}/vector). To confirm that complementation of the yeast ino1{Delta} mutant was caused by the recombinant construct, 5'-fluoro-orotic acid was used to select for the loss of the plasmid. As shown in Fig. 2B, the ino1{Delta} cells containing the construct before 5'-fluoro-orotic acid selection grew on I–plates, whereas cells that lost the plasmid after 5'-fluoro-orotic acid selection did not. Yeast cells that overexpress the yeast INO1 gene excrete inositol into the medium, creating a phenotype known as opi (overproduction of inositol), which is detected by the ability of the excreted inositol to support growth of an inositol-requiring indicator strain (51). As shown in Fig. 2C, the ino1{Delta} mutant harboring the hINO1 gene exhibited the opi phenotype. These results indicate that human MIP synthase is functional in yeast.



View larger version (43K):
[in this window]
[in a new window]
  		FIG. 2.
Expression of hINO1 functionally complements yeast ino1{Delta}. A, growth of the ino1{Delta} mutant harboring the human MIP synthase cDNA (ino1{Delta}/hINO1) or empty vector (ino1{Delta}/vector) on I+ and I–medium. B, cells of ino1{Delta}/hINO1 were streaked on synthetic I+ medium containing 1 mg/ml 5'-fluoro-orotic acid to select for loss of the plasmid. These cells were then plated (along with controls ino1{Delta}, ino1{Delta}/hINO1, and ino1{Delta}/vector) on the indicated synthetic media. C, opi phenotype of ino1{Delta}/hINO1. Cells from ino1{Delta}/hINO1 (top four) or ino1{Delta}/vector (bottom four) were spotted on indicator plates containing the inositol-requiring strain AID-1. Inositol excretion is indicated by growth of the AID-1 lawn around ino1{Delta}/hINO1 cells.

 
To further characterize the function of hINO1 in yeast, cells were shifted from I+ to I–medium, and intracellular inositol, MIP synthase activity, and cell viability were assayed. As shown in Fig. 3A, following the shift to I–, intracellular inositol decreased markedly in ino1{Delta} cells lacking hINO1 but remained constant in cells containing the human gene. Consistent with these data, ino1{Delta}/hINO1 cells continued to grow, but ino1{Delta}/vector cells lost viability after 24 h (Fig. 3B). MIP synthase activity was high in ino1{Delta} cells containing hINO1 but undetectable in ino1{Delta} cells transformed with empty vector (Fig. 3C). Interestingly, intracellular inositol in ino1{Delta}/hINO1 was 30% higher than in isogenic wild type cells lacking the hINO1 gene (Fig. 3D), which most likely accounts for the inositol excretion phenotype of ino1{Delta}/hINO1 observed in Fig. 2C. This can be explained by the constant high level of expression of the hINO1-containing plasmid. In contrast, expression of the native yeast INO1 gene in wild type cells is regulated and expressed highly only in logarithmic phase cells (32).



View larger version (23K):
[in this window]
[in a new window]
  		FIG. 3.
Expression of hINO1 restores inositol synthesis to ino1{Delta} mutant. Cells from strain ino1{Delta}/hINO1 and ino1{Delta}/vector were grown in medium containing 75 µM inositol to the middle logarithmic phase of growth and were shifted at time zero to I–medium. Cells were harvested at indicated times after the shift. A, intracellular inositol per 100 µg of protein was determined by the enzyme-coupled fluorescent assay of Maslanski and Busa (45). The inositol values are represented relative to that observed at time zero (100%). {blacksquare}, ino1{Delta}/hINO1; {square}, ino1{Delta}/vector. B, viable cells were counted at 0 and 24 h after the shift. C, MIP synthase was assayed in crude extracts of cells grown in I+ medium to early stationary phase. D, intracellular inositol was assayed in ino1{Delta}/hINO1, and wild type (WT) cells were grown in I–medium to the early stationary phase. The values shown are the average of two independent experiments.

 
Effect of VPA on Inositol and MIP Synthase Activity
We have shown that both Li and VPA cause a decrease in intracellular inositol in yeast (20). This is consistent with the observed decrease in brain inositol levels following Li (52) and VPA (23) treatment. The Li-induced decrease can be explained by inhibition of inositol monophosphatase (19, 21). However, a decrease in MIP levels was observed during growth in the presence of VPA, suggesting that VPA may inhibit MIP synthase (20). To address this possibility, inositol and MIP synthase activities were assayed in crude extracts of ino1{Delta}/hINO1 grown in the presence of 0.6 mM VPA (the concentration used in therapeutic treatment). As shown in Fig. 4, in the presence of VPA, intracellular inositol was decreased 25% (Fig. 4A), and a 35% decrease in MIP synthase activity was observed (Fig. 4B). The gene was expressed at high levels in all growth phases (data not shown), and expression was not affected by VPA (Fig. 4C), indicating that the inhibitory effect of the drug was at the level of the protein.



View larger version (13K):
[in this window]
[in a new window]
  		FIG. 4.
Intracellular inositol, MIP synthase activity, and hINO1 expression in the presence of VPA. ino1{Delta}/hINO1 cells were grown in I–medium to the early stationary growth phase in the absence or presence of 0.6 mM VPA. Intracellular inositol (A), MIP synthase activity (B), and hINO1 expression (C) were assayed as described under "Experimental Procedures." The inositol and MIP synthase values were determined relative to those observed in untreated cells (100%). Expression of hINO1 was quantitated relative to TCM1, which was used as an internal control. The values shown are the average of three independent experiments. *, statistical significance p < 0.05 compared with untreated cells.

 
Purification of Recombinant Human MIP Synthase
Human MIP synthase was expressed following isopropyl-1-thio-{beta}-D-galactopyranoside induction of E. coli BL21(DE3)-pLysS transformed with hINO1 (Fig. 5A, lanes 2–5). The His-tagged human MIP synthase protein was purified by Ni2+ affinity chromatography and eluted with 250 mM imidazole. The purified protein analyzed by SDS-PAGE migrated with an apparent molecular mass of ~65 kDa (Fig. 5A, lane 6) which is consistent with the expected size (62-kDa protein plus a 3-kDa tag). Western blot analysis using anti-Xpress antibody confirmed that this was the recombinant protein (Fig. 5B, lanes 2–6). The specific activity of the purified enzyme was measured by the rapid colorimetric method of Barnett et al. (49) and confirmed by the chromatographic assay of Chen and Charalampous (48) using [14C]glucose 6-phosphate as a substrate.



View larger version (35K):
[in this window]
[in a new window]
  		FIG. 5.
Expression of human MIP synthase in E. coli. The hINO1 gene was subcloned into the pRSETA vector and expressed in E. coli strain BL21(DE3)pLys. A, SDS-PAGE gel stained with Coomassie Blue. Lane 1, molecular markers; lanes 2 and 3, crude extract (20 µg of protein) from cells transformed with vector only before (lane 2) and after (lane 3) 1 mM isopropyl-1-thio-{beta}-D-galactopyranoside induction; lanes 4 and 5, crude extract (20 µg of protein) from cells transformed with hINO1 before (lane 4) and after (lane 5) 1 mM isopropyl-1-thio-{beta}-D-galactopyranoside induction; lane 6, the recombinant human MIP synthase (2 µg) purified by Ni2+-affinity chromatography. B, Western blot of the samples shown in A using anti-Xpress antibody.

 
Properties of Human MIP Synthase
Effect of pH and Temperature on Enzyme Activity—Human MIP synthase activity was measured at pH 6.0–10.0 using 100 mM Tris acetate buffer. All other components in the reaction mixture were kept constant, and assays were performed using standard conditions as described under "Experimental Procedures." The optimal pH of human MIP synthase was 8.0 (Fig. 6A).



View larger version (12K):
[in this window]
[in a new window]
  		FIG. 6.
Effect of pH and temperature on enzyme activity. A, enzyme activity was measured at the indicated pH values with 100 mM Tris acetate buffer. B, enzyme activity was measured at the indicated temperature. C, the enzyme was heated at the indicated temperature for 20 min before the reaction. Activity of the heated enzyme was measured at optimal pH (8.0) and temperature (37 °C). Data represent the average of two independent experiments.

 
Enzyme activity was measured in a controlled temperature water bath from 20 to 60 °C under standard assay conditions. The temperature profile suggested that maximum activity was obtained at 37 °C, and the enzyme still was 90% active at 45 °C (Fig. 6B). Thermal stability of the enzyme was determined by assaying samples heated for 20 min at 30–60 °C. The enzyme was stable to heating up to 45 °C. However, ~60% activity was lost upon heating at 60 °C (Fig. 6C).

Enzyme Kinetics—Kinetic analysis of purified recombinant enzyme is shown in Fig. 7. When NAD+ was held constant at 0.8 mM and the G-6-P concentration varied, saturation kinetics were shown by the enzyme. The apparent Km for G-6-P was 0.57 mM (Fig. 7A). Saturation kinetics also were shown when G-6-P was held constant at 5 mM and the NAD+ concentration varied. The apparent Km for NAD+ was 8 µM (Fig. 7B).



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 7.
Lineweaver-Burk analysis of recombinant MIP synthase activity. Activity was measured in 40 µg of protein with a varied G-6-P concentration and a fixed NAD+ concentration (0.8 mM) (A) and with a varied NAD+ concentration and a fixed G-6-P concentration (5 mM)(B). Data represent the average of two independent experiments.

 
Effect of Cations on Enzyme Activity—MIP synthase activity was determined in the presence of , Na+, K+, Mg2+, Mn2+, Ca2+, and Zn2+. Like MIP synthase from all other organisms except Archaeoglobus fulgidus (2), human MIP synthase was strongly stimulated by NH+4. The activity was increased 5-fold at 5 mM NH+4 (Fig. 8A). 10 mM K+ stimulated activity 5-fold. Mg2+ and Mn2+ increased activity 2–3-fold at 1 or 10 mM (Fig. 8B). Activity was decreased 5-fold in the presence of 1 mM Zn2+ and was totally inactivated in the presence of 10 mM Zn2+ (Fig. 8B). Na+ and Ca2+ had no effect on the enzyme at 1 mM and increased activity by about 2-fold at 10 mM (Fig. 8B).



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 8.
Effect of cations on recombinant human MIP synthase activity. A, effect of NH+4 on enzyme activity. B, effect of cations on enzyme activity. Data represent the average of two independent experiments.

 
Effect of VPA on Purified Human MIP Synthase—To determine whether the decrease in MIP synthase activity observed during growth in the presence of VPA (Fig. 4B) is caused by direct inhibition of the enzyme, purified human MIP synthase activity was determined in the presence of different concentrations of the drug. The enzyme was not inhibited by the therapeutic concentration of VPA and was only slightly (10%) inhibited by VPA at 10 mM (Fig. 9). This inhibition was not seen when 14 mM NH+4 was included in the reaction mixture (data not shown).



View larger version (11K):
[in this window]
[in a new window]
  		FIG. 9.
Effect of VPA on recombinant human MIP synthase activity. Enzyme activity was measured at the indicated concentrations of VPA. Data represent the average of three independent experiments.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
We report for the first time that human MIP synthase is functional in yeast and supports growth of the yeast ino1 mutant in the absence of inositol. In the presence of a therapeutically relevant concentration of the anti-bipolar drug VPA, yeast ino1 mutant cells containing the human enzyme exhibit a decrease in MIP synthase activity and intracellular inositol. We observed previously that growth of yeast cells in the presence of VPA leads to decreased inositol monophosphate and intracellular inositol and increased INO1 expression consistent with the inhibition of yeast MIP synthase (20). Similar to the observations in yeast cells, a decrease in MIP synthase activity also was observed in crude extracts from post-mortem human brain.2 The purified recombinant human enzyme was not inhibited by therapeutic concentrations of VPA (Fig. 9). Purified yeast MIP synthase was similarly not affected by VPA.3 These findings suggest that a metabolite of VPA or an inhibitor that accumulates in the presence of VPA may be responsible for MIP synthase inhibition. The current findings support the use of the yeast model to elucidate the effects of VPA on inositol biosynthesis.

The properties of the recombinant MIP synthase were similar mostly to those reported for native enzymes. The enzyme was active from pH 7.5 to 10.0. MIP synthase that was partially purified and characterized from human fetal brain was optimal at pH 7.5 (53). The Km of the recombinant enzyme for NAD+ was 8 µM, much lower than 452 µM reported for the partially purified human fetal brain enzyme but consistent with values from other sources, e.g. 11 µM for the bovine testis enzyme (42), 17.9 µM for the rat testis enzyme (40), and 8 µM for the yeast enzyme (27). NH+4 strongly stimulated both the partially purified fetal brain enzyme and the recombinant enzyme. Other mono- and divalent cations also stimulated the enzyme to different extents, which may implicate a general ionic effect. The recombinant enzyme also was stimulated 1.5–2.5-fold by Li+ at 1–50 mM, consistent both with the general ionic effect and with similar results reported previously (40).

Although the therapeutic mechanism of action of Li and VPA are not known, both anti-bipolar drugs cause a decrease in intracellular inositol. In yeast, inositol is a major metabolic sensor for the secretory and unfolded protein response pathways (54).2 If this function is conserved in human cells, inositol depletion by Li and VPA is a first common step that may lead to perturbation of these pathways, one of which (the secretory pathway) plays a fundamental role in neurotransmitter release. Functional conservation of MIP synthase from yeast to humans underscores the power of the yeast model to study the mechanism of action of anti-bipolar drugs in inositol metabolism.


   FOOTNOTES
 
* This study was supported by National Institutes of Health Grant R01 MH 56220 (to M. L. G.) and United States-Israel Binational Science Foundation Grant 2001035 (to M. L. G. and G. A.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

To whom correspondence should be addressed. Tel.: 313-577-5202; Fax: 313-577-6891; E-mail: mlgreen{at}sun.science.wayne.edu.

1 The abbreviations used are: VPA, valproate; G-6-P, D-glucose 6-phosphate; MIP, 1-D-myo-inositol 3-phosphate; hINO1, human INO1; opi, overproduction of inositol. Back

2 G. Shaltiel, A. Shamir, J. Shapiro, D. Ding, E. Dalton, M. Bialer, A. J. Harwood, R. H. Belmaker, M. L. Greenberg, and G. Agam, submitted for publication. Back

3 D. Ding and M. L. Greenberg, unpublished observations. Back


   ACKNOWLEDGMENTS
 
We thank William P. Tansey and Martin A. Hoyt for providing the pRS426GPD vector. We also thank Quan Zhong for assistance with the enzyme assays, Yihui Shi and Ervin Pullumbi for standardizing the MIP synthase assay in crude extracts, and all members of the Greenberg laboratory for helpful discussions and valuable suggestions.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Majumder, A. L., Johnson, M. D., and Henry, S. A. (1997) Biochim. Biophys. Acta 1348, 245–256[Medline] [Order article via Infotrieve]
  2. Chen, L., Zhou, C., Yang, H., and Roberts, M. F. (2000) Biochemistry 39, 12415–12423[CrossRef][Medline] [Order article via Infotrieve]
  3. Bachhawat, N., and Mande, S. C. (1999) J. Mol. Biol. 291, 531–536[CrossRef][Medline] [Order article via Infotrieve]
  4. Lohia, A., Hait, N. C., and Majumder, A. L. (1999) Mol. Biochem. Parasitol. 98, 67–79[CrossRef][Medline] [Order article via Infotrieve]
  5. Hokin, L. E. (1985) Annu. Rev. Biochem. 54, 205–235[CrossRef][Medline] [Order article via Infotrieve]
  6. Berridge, M. J., and Irvine, R. F. (1989) Nature 341, 197–205[CrossRef][Medline] [Order article via Infotrieve]
  7. Berridge, M. J. (1993) Nature 361, 315–325[CrossRef][Medline] [Order article via Infotrieve]
  8. Fisher, S. K., Novak, J. E., and Agranoff, B. W. (2002) J. Neurochem. 82, 736–754[CrossRef][Medline] [Order article via Infotrieve]
  9. York, J. D., Guo, S., Odom, A. R., Spiegelberg, B. D., and Stolz, L. E. (2001) Adv. Enzyme Regul. 41, 57–71[CrossRef][Medline] [Order article via Infotrieve]
  10. Weissman, M. M., Leaf, P. J., Tischler, G. L., Blazer, D. G., Karno, M., Bruce, M. L., and Florio, L. P. (1988) Psychol. Med. 18, 141–153[Medline] [Order article via Infotrieve]
  11. Agam, G., Shamir, A., Shaltiel, G., and Greenberg, M. L. (2002) Bipolar Disord. 1, Suppl. 4, 15–20
  12. Shimon, H., Agam, G., Belmaker, R. H., Hyde, T. M., and Kleinman, J. E. (1997) Am. J. Psychiatry 154, 1148–1150[Abstract]
  13. Davanzo, P., Thomas, M. A., Yue, K., Oshiro, T., Belin, T., Strober, M., and McCracken, J. (2001) Neuropsychopharmacology 24, 359–369[CrossRef][Medline] [Order article via Infotrieve]
  14. Soares, J. C., Mallinger, A. G., Dippold, C. S., Forster Wells, K., Frank, E., and Kupfer, D. J. (2000) Psychopharmacology (Berl.) 149, 12–16[CrossRef][Medline] [Order article via Infotrieve]
  15. Banks, R. E., Aiton, J. F., Cramb, G., and Naylor, G. J. (1990) J. Affect. Disord. 19, 1–8[CrossRef][Medline] [Order article via Infotrieve]
  16. Hallcher, L. M., and Sherman, W. R. (1980) J. Biol. Chem. 255, 10896–10901[Abstract/Free Full Text]
  17. Berridge, M. J. (1985) Rev. Clin. Basic Pharmacol. 5, (suppl.) 5S–13S
  18. Atack, J. R., Broughton, H. B., and Pollack, S. J. (1995) FEBS Lett. 361, 1–7[CrossRef][Medline] [Order article via Infotrieve]
  19. Vadnal, R., and Parthasarathy, R. (1995) Neuropsychopharmacology 12, 277–285[CrossRef][Medline] [Order article via Infotrieve]
  20. Vaden, D. L., Ding, D., Peterson, B., and Greenberg, M. L. (2001) J. Biol. Chem. 276, 15466–15471[Abstract/Free Full Text]
  21. Murray, M., and Greenberg, M. L. (2000) Mol. Microbiol. 36, 651–661[CrossRef][Medline] [Order article via Infotrieve]
  22. Carman, G. M., and Henry, S. A. (1999) Prog. Lipid Res. 38, 361–399[CrossRef][Medline] [Order article via Infotrieve]
  23. O'Donnell, T., Rotzinger, S., Nakashima, T. T., Hanstock, C. C., Ulrich, M., and Silverstone, P. H. (2000) Brain Res. 880, 84–91[CrossRef][Medline] [Order article via Infotrieve]
  24. Loewus, M. W., Wright, R. W., Jr., Bondioli, K. R., Bedgar, D. L., and Karl, A. (1983) J. Reprod. Fertil. 69, 215–220[Abstract/Free Full Text]
  25. Pittner, F., Tovarova, II, Kornitskaya, E. Y., Khokhlov, A. S., and Hoffmann-Ostenhof, O. (1979) Mol. Cell. Biochem. 25, 43–46[Medline] [Order article via Infotrieve]
  26. RayChaudhuri, A., Hait, N. C., Dasgupta, S., Bhaduri, T. J., Deb, R., and Majumder, A. L. (1997) Plant Physiol. 115, 727–736[Abstract]
  27. Donahue, T. F., and Henry, S. A. (1981) J. Biol. Chem. 256, 7077–7085[Abstract/Free Full Text]
  28. Klig, L. S., Zobel, P. A., Devry, C. G., and Losberger, C. (1994) Yeast 10, 789–800[CrossRef][Medline] [Order article via Infotrieve]
  29. Guan, G., Dai, P., and Shechter, I. (2003) Arch. Biochem. Biophys. 417, 251–259[CrossRef][Medline] [Order article via Infotrieve]
  30. Chun, J. A., Jin, U. H., Lee, J. W., Yi, Y. B., Hyung, N. I., Kang, M. H., Pyee, J. H., Suh, M. C., Kang, C. W., Seo, H. Y., Lee, S. W., and Chung, C. H. (2003) Planta 216, 874–880[Medline] [Order article via Infotrieve]
  31. Graves, J. A., and Henry, S. A. (2000) Genetics 154, 1485–1495[Abstract/Free Full Text]
  32. Griac, P., Swede, M. J., and Henry, S. A. (1996) J. Biol. Chem. 271, 25692–25698[Abstract/Free Full Text]
  33. Lopes, J. M., and Henry, S. A. (1991) Nucleic Acids Res. 19, 3987–3994[Abstract/Free Full Text]
  34. Lopes, J. M., Hirsch, J. P., Chorgo, P. A., Schulze, K. L., and Henry, S. A. (1991) Nucleic Acids Res. 19, 1687–1693[Abstract/Free Full Text]
  35. Hirsch, J. P., and Henry, S. A. (1986) Mol. Cell. Biol. 6, 3320–3328[Abstract/Free Full Text]
  36. McGraw, P., and Henry, S. A. (1989) Genetics 122, 317–330[Abstract/Free Full Text]
  37. Greenberg, M. L., and Lopes, J. M. (1996) Microbiol. Rev. 60, 1–20[Free Full Text]
  38. Ding, D., and Greenberg, M. L. (2003) Mol. Microbiol. 47, 373–381[CrossRef][Medline] [Order article via Infotrieve]
  39. Ju, S., and Greenberg, M. L. (2003) Mol. Microbiol. 49, 1595–1603[CrossRef][Medline] [Order article via Infotrieve]
  40. Maeda, T., and Eisenberg, F., Jr. (1980) J. Biol. Chem. 255, 8458–8464[Free Full Text]
  41. Naccarato, W. F., Ray, R. E., and Wells, W. W. (1974) Arch. Biochem. Biophys. 164, 194–201[CrossRef][Medline] [Order article via Infotrieve]
  42. Mauck, L. A., Wong, Y. H., and Sherman, W. R. (1980) Biochemistry 19, 3623–3629[CrossRef][Medline] [Order article via Infotrieve]
  43. Adhikari, J., and Majumder, A. L. (1983) FEBS Lett. 163, 46–49[CrossRef][Medline] [Order article via Infotrieve]
  44. Gross-Isseroff, R., Dillon, K. A., Fieldust, S. J., and Biegon, A. (1990) Arch. Gen. Psychiatry 47, 1049–1053[Abstract/Free Full Text]
  45. Maslanski, J. A., and Busa, W. B. (1990) in Methods in Inositide Research (Irvine, R. F., ed) pp. 113–126, Raven Press, Ltd., New York
  46. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254[CrossRef][Medline] [Order article via Infotrieve]
  47. Laemmli, U. K. (1970) Nature 227, 680–685[CrossRef][Medline] [Order article via Infotrieve]
  48. Chen, I. W., and Charalampous, C. F. (1966) J. Biol. Chem. 241, 2194–2199[Abstract/Free Full Text]
  49. Barnett, J. E., Brice, R. E., and Corina, D. L. (1970) Biochem. J. 119, 183–186[Medline] [Order article via Infotrieve]
  50. Mumberg, D., Muller, R., and Funk, M. (1995) Gene 156, 119–122[CrossRef][Medline] [Order article via Infotrieve]
  51. Greenberg, M. L., Reiner, B., and Henry, S. A. (1982) Genetics 100, 19–33[Abstract/Free Full Text]
  52. Allison, J. H., Boshans, R. L., Hallcher, L. M., Packman, P. M., and Sherman, W. R. (1980) J. Neurochem. 34, 456–458[CrossRef][Medline] [Order article via Infotrieve]
  53. Adhikari, J., and Majumder, A. L. (1988) Indian J. Biochem. Biophys. 25, 408–412[Medline] [Order article via Infotrieve]
  54. Chang, H. J., Jones, E. W., and Henry, S. A. (2002) Genetics 162, 29–43[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
R. S. Seelan, J. Lakshmanan, M. F. Casanova, and R. N. Parthasarathy
Identification of myo-Inositol-3-phosphate Synthase Isoforms: CHARACTERIZATION, EXPRESSION, AND PUTATIVE ROLE OF A 16-kDa {gamma}c ISOFORM
J. Biol. Chem., April 3, 2009; 284(14): 9443 - 9457.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Shi, D. L. Vaden, S. Ju, D. Ding, J. H. Geiger, and M. L. Greenberg
Genetic Perturbation of Glycolysis Results in Inhibition of de Novo Inositol Biosynthesis
J. Biol. Chem., December 23, 2005; 280(51): 41805 - 41810.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
S. Sarkar, R. A. Floto, Z. Berger, S. Imarisio, A. Cordenier, M. Pasco, L. J. Cook, and D. C. Rubinsztein
Lithium induces autophagy by inhibiting inositol monophosphatase
J. Cell Biol., September 26, 2005; 170(7): 1101 - 1111.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
Y. Hao, T. Creson, L. Zhang, P. Li, F. Du, P. Yuan, T. D. Gould, H. K. Manji, and G. Chen
Mood Stabilizer Valproate Promotes ERK Pathway-Dependent Cortical Neuronal Growth and Neurogenesis
J. Neurosci., July 21, 2004; 24(29): 6590 - 6599.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/21/21759    most recent
M312078200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ju, S.
Right arrow Articles by Greenberg, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ju, S.
Right arrow Articles by Greenberg, M. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement